…
Dogecoin Cash, Inc., through its subsidiaries, provides telemedicine online referral services for customers desiring medical marijuana cards in the United States. The company offers PrestoDoctor, an online telemedicine platform, which provides access to physicians for getting a medical marijuana recommendation using video conferencing technology. It also develops Lozenges for relief; Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC, as well as intends to offer hi branded men's and women's fashion from suppliers through its www.cbds.com website. In addition, the company holds intellectual property license for manufacture of medical marijuana edibles. It serves cannabidiol and cannabis industries. The company was formerly known as Cannabis Sativa, Inc. and changed its name to Dogecoin Cash, Inc. in November 2024. Dogecoin Cash, Inc. is based in Mesquite, Nevada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Dogecoin Cash, Inc. (OTCQB: DOGP.US) are sparse and its core business and operations are not clearly described in readily available filings. Because detailed strategic and financial information is limited, major long-term growth drivers are not identified and investors may find the company attractive only if it provides a credible plan to generate revenue or clearer disclosure of its strategy.
The most important investment risk is limited transparency and public disclosure, which increases liquidity, governance and execution risk for shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -10.04M | -1.78M | -1.32M | -1.26M | -2.35M |
| Minority interest | 9.47M | 0.05M | -0.07M | 0.05M | -0.03M |
| Net income | -0.57M | -1.73M | -1.39M | -1.22M | -2.45M |
| Selling general administrative | 1.02M | 1.18M | 1.48M | 2.20M | 2.72M |
| Gross profit | 0.47M | 0.49M | 0.77M | 0.96M | 1.14M |
| Reconciled depreciation | 0.00M | 0.00M | 0.15M | 0.16M | 0.19M |
| Operating income | -0.55M | -0.69M | -0.86M | -1.40M | -1.75M |
| Interest expense | 0.09M | 0.22M | 0.06M | 0.03M | 0.07M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.09M | -0.22M | -0.06M | -0.03M | -0.07M |
| Total revenue | 0.74M | 0.80M | 1.17M | 1.56M | 1.84M |
| Total operating expenses | 1.29M | 1.50M | 2.03M | 2.96M | 3.59M |
| Cost of revenue | 0.27M | 0.31M | 0.40M | 0.60M | 0.70M |
| Total other income expense net | -9.40M | -0.87M | -0.41M | 0.17M | -0.54M |
| Net income from continuing ops | -10.04M | -1.78M | -1.32M | -1.26M | -2.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.23M | 1.71M | 2.02M | 2.57M | 2.56M |
| Intangible assets | 0.00M | 0.00M | 0.01M | 0.16M | 0.32M |
| Other current assets | - | - | 0.01M | - | - |
| Total liab | 2.26M | 1.84M | 1.26M | 0.99M | 1.52M |
| Total stockholder equity | -1.87M | -1.44M | -0.60M | 0.29M | -0.29M |
| Capital stock | 0.16M | 0.15M | 0.09M | 0.05M | 0.03M |
| Retained earnings | -84.39M | -83.82M | -82.08M | -80.69M | -79.48M |
| Good will | 1.28M | 1.28M | 1.78M | 1.84M | 1.84M |
| Cash | 0.03M | 0.03M | 0.08M | 0.10M | 0.19M |
| Total current liabilities | 0.84M | 0.72M | 0.49M | 0.56M | 1.52M |
| Net debt | 0.58M | 0.50M | 0.20M | 0.16M | 1.02M |
| Short long term debt | 0.61M | 0.54M | 0.28M | 0.26M | 1.22M |
| Total current assets | 0.94M | 0.35M | 0.16M | 0.48M | 0.40M |
| Short term investments | 0.92M | 0.32M | 0.07M | 0.38M | 0.21M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 0.19M | 0.15M | 0.18M | 0.25M | 0.10M |
| Non current assets total | 1.28M | 1.36M | 1.86M | 2.09M | 2.16M |
| Capital lease obligations | - | 0.00M | 0.01M | 0.04M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.01M | 0.00M | 0.04M |
| Net borrowings | 0.03M | 0.06M | 0.06M | 0.20M | 0.04M |
| Total cash from financing activities | 0.03M | 0.06M | 0.06M | 0.20M | 0.10M |
| Net income | -0.57M | -1.73M | -1.39M | -1.22M | -2.45M |
| Change in cash | -0.01M | -0.05M | -0.01M | -0.10M | -0.13M |
| Begin period cash flow | 0.03M | 0.08M | 0.10M | 0.19M | 0.32M |
| End period cash flow | 0.03M | 0.03M | 0.08M | 0.10M | 0.19M |
| Total cash from operating activities | -0.04M | -0.11M | -0.06M | -0.24M | -0.25M |
| Issuance of capital stock | - | - | - | 0.00M | 0.01M |
| Depreciation | 0.00M | 0.00M | 0.15M | 0.16M | 0.19M |
| Change to inventory | - | - | - | 0.00M | 0.03M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.05M | 0.28M | -0.07M | 0.17M | 0.10M |
| Other non cash items | 0.41M | 0.52M | 0.63M | 0.86M | 1.51M |
| Free cash flow | -0.04M | -0.11M | -0.06M | -0.24M | -0.25M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DOGP Dogecoin Cash, Inc. |
-0.00 1.67% |
0.01 | - | - | 2.84 | 2.13 | 2.39 | -2.10 |
| VEEV Veeva Systems Inc Class A |
-0.05 0.02% |
266.22 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
-6.60 5.03% |
124.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-5.60 9.39% |
54.01 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.31% |
5.28 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Dogecoin Cash, Inc., through its subsidiaries, provides telemedicine online referral services for customers desiring medical marijuana cards in the United States. The company offers PrestoDoctor, an online telemedicine platform, which provides access to physicians for getting a medical marijuana recommendation using video conferencing technology. It also develops Lozenges for relief; Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC, as well as intends to offer hi branded men's and women's fashion from suppliers through its www.cbds.com website. In addition, the company holds intellectual property license for manufacture of medical marijuana edibles. It serves cannabidiol and cannabis industries. The company was formerly known as Cannabis Sativa, Inc. and changed its name to Dogecoin Cash, Inc. in November 2024. Dogecoin Cash, Inc. is based in Mesquite, Nevada.
| Name | Title | Year Born |
|---|---|---|
| Mr. David M. Tobias | Chairperson, CFO, CEO, President & Secretary | 1951 |
| Ms. Catherine J. Carroll | Treasurer & Director | 1941 |
| Ms. Carolyn Merrill | Controller | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.